To determine whether TSP50 functions through the PI3K/AKT signaling pathway, we treated TSP50-overexpressed breast cancer cells with the PI3K/AKT signaling inhibitor LY294002 and TSP50-knockdowned breast cancer cells with the agonist SC79 for rescue experiments. Here, AKT1 is linked to breast carcinoma.